Ad-HER3 not only induced potent T-cell anti-tumor responses, the HER3, vaccine-induced antibodies (HER3-VIAs) also provided additional activity to eliminate tumors in which HER3 signaling mediates aggressive behavior or acquired resistance to HER2-targeted therapy and triple-negative breast cancers [98]. This evidence concerns the gene ERBB3 and triple-negative breast carcinoma.